Investment
Features
FeesSafety
Academy
More
Pluang+

Circle and Proof to demo AI agent paying merchants with USDC, proving buyer authorization at Money20/20

Protocol Fundamentals
19 Oct 2026
Tokenpost
View Source
Bullish
Circle and Proof to demo AI agent paying merchants with USDC, proving buyer authorization at Money20/20

Circle and Proof plan to demonstrate an AI agent making payments in USD Coin (USDC) while proving buyer authorization at the Money20/20 conference in Las Vegas from October 19-21. Their system uses Proof’s x401 protocol for identity verification and Coinbase-developed x402 for payment authorization, allowing merchants to confirm who approved the purchase. This technology aims to enable automated checkouts with clear authorization records, enhancing trust and security in AI-driven payments. The demo will showcase how AI agents can securely pay merchants while providing proof of buyer consent, with potential future extensions involving merchant payments to identity providers.

The news about Circle and Proof's AI agent checkout with USDC provides context for readers interested in digital payment innovations. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 20, 2026 06:02 WIB: out of 50 priced cryptocurrencies, 42 rose and 7 fell. Notable movers include EOS at Rp12.649 (+8.13%), CRV at Rp6.647 (+7.85%) with a strong sell order activity of 99%, and DOT at Rp20.661 (+4.90%).

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App